Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 30, 2017

DrugPatentWatch Database Preview

Naltrexone - Generic Drug Details

« Back to Dashboard

What are the generic sources for naltrexone and what is the scope of naltrexone freedom to operate?

Naltrexone
is the generic ingredient in four branded drugs marketed by Alkermes, Accord Hlthcare, Barr, Teva Womens, Sandoz, Sun Pharma Global, Mallinckrodt, Elite Labs, and Pfizer Inc, and is included in nine NDAs. There are twenty-two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Naltrexone has one hundred and forty-nine patent family members in thirty-three countries.

There are eighteen drug master file entries for naltrexone. One supplier is listed for this compound.

Summary for Generic Name: naltrexone

Tradenames:4
Patents:22
Applicants:9
NDAs:9
Drug Master File Entries: see list18
Suppliers / Packagers: see list1
Bulk Api Vendors: see list25
Clinical Trials: see list153
Patent Applications: see list9,118
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:naltrexone at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Womens
REVIA
naltrexone hydrochloride
TABLET;ORAL018932-001Nov 20, 1984DISCNNoNo► Subscribe► Subscribe
Barr
NALTREXONE HYDROCHLORIDE
naltrexone hydrochloride
TABLET;ORAL074918-001May 8, 1998ABRXNoNo► Subscribe► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes7,799,345► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes5,792,477► SubscribeY ► Subscribe
Alkermes
VIVITROL
naltrexone
FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR021897-001Apr 13, 2006RXYesYes6,331,317► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Anticipate P&T budget requirements
  • Find generic sources and suppliers
  • Identify first generic entrants

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot